0001127602-22-018097.txt : 20220624
0001127602-22-018097.hdr.sgml : 20220624
20220624123319
ACCESSION NUMBER: 0001127602-22-018097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220622
FILED AS OF DATE: 20220624
DATE AS OF CHANGE: 20220624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kenny John P.
CENTRAL INDEX KEY: 0001719325
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14902
FILM NUMBER: 221038916
MAIL ADDRESS:
STREET 1: 3471 RIVER HILLS DRIVE
CITY: CINCINNATI
STATE: OH
ZIP: 45244
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MERIDIAN BIOSCIENCE INC
CENTRAL INDEX KEY: 0000794172
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 310888197
STATE OF INCORPORATION: OH
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 3471 RIVER HILLS DR
CITY: CINCINNATI
STATE: OH
ZIP: 45244
BUSINESS PHONE: 5132713700
MAIL ADDRESS:
STREET 1: 3471 RIVER HILLS DRIVE
CITY: CINCINNATI
STATE: OH
ZIP: 45244
FORMER COMPANY:
FORMER CONFORMED NAME: MERIDIAN DIAGNOSTICS INC
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-06-22
0000794172
MERIDIAN BIOSCIENCE INC
VIVO
0001719325
Kenny John P.
3471 RIVER HILLS DRIVE
CINCINNATI
OH
45244
1
1
Chief Executive Officer
Common Stock
2022-06-22
4
M
0
44651
14.50
A
309782
D
Common Stock
2022-06-22
4
S
0
44651
29.7176
D
265131
D
Common Stock
2022-06-23
4
M
0
5349
14.50
A
270480
D
Common Stock
2022-06-23
4
M
0
14607
10.10
A
285087
D
Common Stock
2022-06-23
4
S
0
19956
29.9764
D
265131
D
Stock Options (Right to Buy)
14.50
2022-06-22
4
M
0
44651
0
D
2027-10-09
Common Stock
44651
5349
D
Stock Options (Right to Buy)
14.50
2022-06-23
4
M
0
5349
0
D
2027-10-09
Common Stock
5349
0
D
Stock Options (Right to Buy)
10.10
2022-06-23
4
M
0
14607
0
D
2029-11-05
Common Stock
14607
141035
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $29.94. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.61 to $30.13. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
These non-qualified options were awarded under the 2012 Stock Incentive Plan upon Mr. Kenny being hired as Chief Executive Officer. The options vested in four (4) equal installments from the date of grant until fully vested on October 9, 2021.
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date.
/s/ Jeffery T. Pinkston as Attorney-in-fact for John P. Kenny
2022-06-24